We’ve conducted over 800 projects across Asia Pacific, EMEA, Latin America and North America. The proof of our ability is in our work, so we invite you to browse our case studies. They’re filled with examples of how we enrolled and engaged patients in studies that were just starting, falling behind, and/or in a race to market.
You can filter the case studies by therapeutic area and indication using the drop-downs below.
This was a critical phase III trial designed to be the most important study in this sponsor’s upcoming FDA submission for an innovative new Type 2 diabetes treatment.
Read More »This sponsor was in a crucial race in the diabetes space as it began phase III clinical trials for a new class of drug for type 2 diabetes.
They were also rolling into a crowded field of companies developing competitive compounds. The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to $50 billion by 2022.
Read More »The sponsor began a fierce race in the diabetes space with its phase III clinical trials for a new class of drug for type 2 diabetes. The competition was stiff, but the race was worth winning. If approved, sales were projected to hit $1.5 billion by 2018 in a market for type 2 diabetes drugs that will nearly double to $50 billion by 2022.
Read More »This sponsor was hoping to expand its presence in inflammation and autoimmunity with four global, pivotal phase III protocols in patients with moderately-to-severely active rheumatoid arthritis.
Read More »With this Phase III, two-protocol program, the sponsor hoped to extend the label of its antidepressant drug to children and adolescents.
Read More »Opioid-induced constipation (OIC) is projected to hit $2.8 billion by 2022, according to Credence Research (March 2016 report). Growth for this market will come from the introduction of several new drugs, including this sponsor’s compound, which would be the first to market in a new class.
Read More »It’s no surprise that doctors enthuse about the new CGRP class of migraine prevention drugs currently under development. More than 36 million Americans suffer from migraine attacks, and of these, about 4 million have chronic migraine.
Read More »This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.
Read More »This phase III global program, involving four protocols and approximately 300 sites, was critical for a sponsor striving to make its compound the leader in a potential $1B gout market.
Read More »This seven-year outcomes study is critical to the success of a compound that is expected to build on the sponsor’s leadership position in diabetes care. Because of the study’s importance, as well as the costs associated with this multiyear program, keeping enrollment and study timelines on track was of paramount importance to the sponsor.
Read More »Acurian consistently receives high marks for delivering the number of patients needed to close an enrollment gap. However, the quality of our patients is just as important. That’s why we centrally pre-screen every respondent using comprehensive, IRB-approved pre-screeners to confirm study eligibility. In fact, on average, only 10% of all respondents are referred to sites for further screening and processing.
Read More »The sponsor’s original goal for this six-year trial was to enroll 18,000 patients. However, like most long-term studies, it turned out to be a very difficult and costly trial to enroll. After three and a half years, patient enrollment rates were far below commitments, and 750 U.S. sites had randomized only 2,200 subjects.
Read More »